The antileukemia roles of PP242 alone or in combination with daunorubicin in acute leukemia

Anti-Cancer Drugs

Volumn 26, Issue 4, 2015, Pages 410-421

  Shi, Fangfang ^a   Yang, Xiaojing ^a   Gong, Yuping ^a   Shi, Rui ^a   Yang, Xi ^a   Naren, Duolan ^a   Wu, Jiahui ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

acute leukemia; Akt mTORC1 eIF4E signaling pathway; eIF4F translation complex; mTOR inhibitor PP242

Indexed keywords

2 (4 AMINO 1 ISOPROPYL 1H PYRAZOLO[3,4 D]PYRIMIDIN 3 YL) 1H INDOL 5 OL; DAUNORUBICIN; INITIATION FACTOR 4E; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; PROTEIN KINASE B; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; MCL1 PROTEIN, HUMAN; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; PROTEIN MCL 1; PURINE DERIVATIVE; TARGET OF RAPAMYCIN KINASE;

ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOMONOCYTIC LEUKEMIA; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; MANTLE CELL LYMPHOMA; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSLATION INITIATION; DRUG EFFECTS; DRUG POTENTIATION; LEUKEMIA; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DAUNORUBICIN; DRUG SYNERGISM; EUKARYOTIC INITIATION FACTOR-4E; HUMANS; INDOLES; LEUKEMIA; LEUKEMIA, MYELOMONOCYTIC, ACUTE; LEUKEMIA, PROMYELOCYTIC, ACUTE; LYMPHOMA, MANTLE-CELL; MULTIPROTEIN COMPLEXES; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTO-ONCOGENE PROTEINS C-AKT; PURINES; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84925541620     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0000000000000200     Document Type: Article

References (29)

1. Weinstein HJ, Mayer RJ, Rosenthal DS, Camitta BM, Coral FS, Nathan DG, Frei E III. Treatment of acute myelogenous leukemia in children and adults. N Engl J Med 1980; 303:473-478.
2. Yates JW, Wallace HJ Jr, Ellison RR, Holland JF. Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia. Cancer Chemother Rep 1973; 57:485-488.
3. Wiernik PH, Banks PL, Case DC Jr, Arlin ZA, Periman PO, Todd MB, et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 1992; 79:313-319.
4. Kantarjian H, O'Brien S, Cortes J, Wierda W, Faderl S, Garcia-Manero G, et al. Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years. Cancer 2008; 113 (Suppl):1933-1952.
5. Xu G, Zhang W, Bertram P, Zheng XF, McLeod H. Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors. Int J Oncol 2004; 24:893-900.
6. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006; 124:471-484.
7. Kuo HP, Lee DF, Chen CT, Liu M, Chou CK, Lee HJ, et al. ARD1 stabilization of TSC2 suppresses tumorigenesis through the mTOR signaling pathway. Sci Signal 2010; 3 :ra9.
8. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004; 18:1926-1945.
9. Sonenberg N, Hinnebusch AG. Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell 2009; 136:731-745.
10. Sonenberg N. eIF4E, the mRNA cap-binding protein: from basic discovery to translational research. Biochem Cell Biol 2008; 86:178-183.
11. Coleman LJ, Peter MB, Teall TJ, Brannan RA, Hanby AM, Honarpisheh H, et al. Combined analysis of eIF4E and 4E-binding protein expression predicts breast cancer survival and estimates eIF4E activity. Br J Cancer 2009; 100:1393-1399.
12. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005; 307:1098-1101.
13. Ravikumar B, Sarkar S, Davies JE, Futter M, Garcia-Arencibia M, Green-Thompson ZW, et al. Regulation of mammalian autophagy in physiology and pathophysiology. Physiol Rev 2010; 90:1383-1435.
14. Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, Gao Y, et al. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem 2009; 284:8023-8032.
15. Yu K, Shi C, Toral-Barza L, Lucas J, Shor B, Kim JE, et al. Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2. Cancer Res 2010; 70:621-631.
16. Feldman ME, Apsel B, Uotila A, Loewith R, Knight ZA, Ruggero D, Shokat KM. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol 2009; 7 :e38.
17. Apsel B, Blair JA, Gonzalez B, Nazif TM, Feldman ME, Aizenstein B, et al. Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol 2008; 4:691-699.
18. Janes MR, Limon JJ, So L, Chen J, Lim RJ, Chavez MA, et al . Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat Med 2010; 16:205-213.
19. Hoang B, Frost P, Shi Y, Belanger E, Benavides A, Pezeshkpour G, et al. Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor. Blood 2010; 116:4560-4568.
20. Zhou YP. The calculation of ID50 in new drugs with software SPSS. Prog Pharm Sci 2003; 27:314-316.
21. Guo Y, Shan Q, Gong Y, Lin J, Yang X, Zhou R. Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway. Cancer Biol Ther 2012; 13:1244-1254.
22. Kharas MG, Janes MR, Scarfone VM, Lilly MB, Knight ZA, Shokat KM, Fruman DA. Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells. J Clin Invest 2008; 118:3038-3050.
23. Hirase C, Maeda Y, Takai S, Kanamaru A. Hypersensitivity of Ph-positive lymphoid cell lines to rapamycin: possible clinical application of mTOR inhibitor. Leuk Res 2009; 33:450-459.
24. Tamburini J, Green AS, Bardet V, Chapuis N, Park S,Willems L, et al. Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia. Blood 2009; 114:1618-1627.
25. Hoang B, Benavides A, Shi Y, Yang Y, Frost P, Gera J, Lichtenstein A. The PP242 mammalian target of rapamycin (mTOR) inhibitor activates extracellular signal-regulated kinase (ERK) in multiple myeloma cells via a target of rapamycin complex 1 (TORC1)/eukaryotic translation initiation factor 4E (eIF-4E)/RAF pathway and activation is a mechanism of resistance. J Biol Chem 2012; 287:21796-21805.
26. Gingras AC, Raught B, Sonenberg N. eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation. Annu Rev Biochem 1999; 68:913-963.
27. Wang L, Harris TE, Roth RA, Lawrence JC Jr. PRAS40 regulates mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding. J Biol Chem 2007; 282:20036-20044.
28. Yang X, Lin J, Gong Y, Ma H, Shuai X, Zhou R, et al. Antileukaemia effect of rapamycin alone or in combination with daunorubicin on Ph+ acute lymphoblastic leukaemia cell line. Hematol Oncol 2012; 30:123-130.
29. Muta D, Makino K, Nakamura H, Yano S, Kudo M, Kuratsu J. Inhibition of eIF4E phosphorylation reduces cell growth and proliferation in primary central nervous system lymphoma cells. J Neurooncol 2011; 101:33-39.